Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hot Flashes | 75 | 2024 | 330 | 11.370 |
Why?
|
Menopause | 82 | 2024 | 1646 | 7.960 |
Why?
|
Perimenopause | 29 | 2022 | 142 | 6.020 |
Why?
|
Estradiol | 34 | 2024 | 1937 | 5.820 |
Why?
|
Women's Health | 37 | 2024 | 2070 | 3.540 |
Why?
|
Sleep Initiation and Maintenance Disorders | 22 | 2022 | 1081 | 2.980 |
Why?
|
Postmenopause | 33 | 2022 | 2514 | 2.620 |
Why?
|
Estrogen Replacement Therapy | 17 | 2022 | 1208 | 2.410 |
Why?
|
Depression | 43 | 2024 | 8132 | 2.160 |
Why?
|
Cyclohexanols | 7 | 2015 | 126 | 1.990 |
Why?
|
Depressive Disorder | 14 | 2018 | 3727 | 1.780 |
Why?
|
Sleep | 33 | 2023 | 4759 | 1.740 |
Why?
|
Sleep Deprivation | 5 | 2024 | 847 | 1.530 |
Why?
|
Progesterone | 7 | 2022 | 742 | 1.430 |
Why?
|
Premenopause | 9 | 2024 | 1039 | 1.400 |
Why?
|
Vasomotor System | 14 | 2024 | 208 | 1.370 |
Why?
|
Menstrual Cycle | 7 | 2020 | 539 | 1.350 |
Why?
|
Gonadotropin-Releasing Hormone | 5 | 2016 | 1146 | 1.270 |
Why?
|
Premenstrual Syndrome | 4 | 2017 | 109 | 1.210 |
Why?
|
Citalopram | 12 | 2018 | 402 | 1.160 |
Why?
|
Affect | 10 | 2021 | 1486 | 1.030 |
Why?
|
Hypothalamo-Hypophyseal System | 6 | 2023 | 695 | 1.000 |
Why?
|
Estrogens | 12 | 2022 | 1522 | 0.870 |
Why?
|
Menstruation Disturbances | 3 | 2012 | 143 | 0.860 |
Why?
|
Ethinyl Estradiol | 3 | 2017 | 113 | 0.860 |
Why?
|
Sweating | 10 | 2018 | 155 | 0.830 |
Why?
|
Female | 171 | 2024 | 392544 | 0.800 |
Why?
|
Androstenes | 2 | 2017 | 181 | 0.790 |
Why?
|
Estrone | 4 | 2022 | 234 | 0.750 |
Why?
|
Leuprolide | 4 | 2016 | 312 | 0.720 |
Why?
|
Follicle Stimulating Hormone | 10 | 2022 | 726 | 0.710 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 326 | 0.700 |
Why?
|
Anxiety | 15 | 2023 | 4569 | 0.680 |
Why?
|
Valproic Acid | 4 | 2008 | 443 | 0.670 |
Why?
|
Antidepressive Agents | 9 | 2018 | 2893 | 0.670 |
Why?
|
Irritable Mood | 1 | 2021 | 193 | 0.660 |
Why?
|
Bipolar Disorder | 10 | 2011 | 5092 | 0.660 |
Why?
|
Middle Aged | 109 | 2024 | 220853 | 0.650 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 628 | 0.650 |
Why?
|
Chickens | 1 | 2021 | 857 | 0.640 |
Why?
|
Hydrocortisone | 2 | 2023 | 1818 | 0.610 |
Why?
|
Longitudinal Studies | 32 | 2024 | 14610 | 0.600 |
Why?
|
Double-Blind Method | 28 | 2023 | 12341 | 0.600 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 858 | 0.590 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2021 | 602 | 0.590 |
Why?
|
Quality of Life | 19 | 2024 | 13367 | 0.580 |
Why?
|
Pituitary-Adrenal System | 5 | 2023 | 547 | 0.580 |
Why?
|
Humans | 177 | 2024 | 761208 | 0.560 |
Why?
|
Fertility Agents, Female | 2 | 2016 | 101 | 0.560 |
Why?
|
Appetite | 1 | 2018 | 247 | 0.540 |
Why?
|
Adult | 83 | 2024 | 221119 | 0.530 |
Why?
|
Psychomotor Performance | 1 | 2024 | 1880 | 0.520 |
Why?
|
Anti-Mullerian Hormone | 2 | 2020 | 407 | 0.510 |
Why?
|
Ovary | 3 | 2015 | 957 | 0.500 |
Why?
|
Hypnotics and Sedatives | 4 | 2011 | 1178 | 0.490 |
Why?
|
Attention | 2 | 2024 | 2394 | 0.470 |
Why?
|
Actigraphy | 6 | 2022 | 522 | 0.470 |
Why?
|
Fatigue | 3 | 2021 | 1550 | 0.450 |
Why?
|
Depressive Disorder, Major | 9 | 2024 | 4767 | 0.450 |
Why?
|
Breast Neoplasms | 9 | 2023 | 20982 | 0.450 |
Why?
|
Yoga | 7 | 2018 | 281 | 0.440 |
Why?
|
Adiposity | 3 | 2020 | 1879 | 0.440 |
Why?
|
Arousal | 1 | 2019 | 1171 | 0.430 |
Why?
|
Medicine | 1 | 2021 | 942 | 0.420 |
Why?
|
Patient Participation | 1 | 2022 | 1445 | 0.410 |
Why?
|
Polycystic Ovary Syndrome | 3 | 2008 | 376 | 0.410 |
Why?
|
Pandemics | 3 | 2021 | 8663 | 0.410 |
Why?
|
Polysomnography | 7 | 2021 | 1848 | 0.410 |
Why?
|
Antimanic Agents | 2 | 2006 | 520 | 0.400 |
Why?
|
Sleep Stages | 1 | 2016 | 695 | 0.400 |
Why?
|
Contraceptives, Oral | 2 | 2020 | 554 | 0.390 |
Why?
|
Cardiovascular System | 1 | 2019 | 836 | 0.390 |
Why?
|
Mood Disorders | 4 | 2009 | 1124 | 0.380 |
Why?
|
Energy Metabolism | 2 | 2022 | 2877 | 0.380 |
Why?
|
Patient Compliance | 2 | 2018 | 2688 | 0.380 |
Why?
|
Hyperandrogenism | 3 | 2006 | 39 | 0.380 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2012 | 155 | 0.370 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.360 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2756 | 0.360 |
Why?
|
Azabicyclo Compounds | 2 | 2009 | 68 | 0.350 |
Why?
|
Hormones | 4 | 2023 | 868 | 0.350 |
Why?
|
Anxiety Disorders | 4 | 2019 | 2723 | 0.350 |
Why?
|
Placebos | 12 | 2018 | 1666 | 0.350 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2017 | 116 | 0.350 |
Why?
|
Weight Gain | 2 | 2018 | 2349 | 0.340 |
Why?
|
Wakefulness | 1 | 2016 | 1264 | 0.320 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 917 | 0.320 |
Why?
|
Reproduction | 2 | 2020 | 646 | 0.320 |
Why?
|
Vaginal Diseases | 3 | 2020 | 103 | 0.320 |
Why?
|
Puerperal Disorders | 2 | 2009 | 301 | 0.320 |
Why?
|
Age of Onset | 1 | 2016 | 3307 | 0.310 |
Why?
|
Luteinizing Hormone | 3 | 2021 | 820 | 0.310 |
Why?
|
Health Surveys | 3 | 2016 | 4037 | 0.300 |
Why?
|
Health Status | 5 | 2018 | 4077 | 0.300 |
Why?
|
gamma-Aminobutyric Acid | 3 | 2015 | 1139 | 0.290 |
Why?
|
Saliva | 2 | 2023 | 828 | 0.290 |
Why?
|
Thiophenes | 2 | 2013 | 569 | 0.290 |
Why?
|
Hypothalamus | 1 | 2012 | 999 | 0.280 |
Why?
|
Pregnanediol | 2 | 2021 | 18 | 0.270 |
Why?
|
Hysterectomy | 5 | 2020 | 857 | 0.260 |
Why?
|
Fatty Acids, Omega-3 | 6 | 2018 | 1390 | 0.260 |
Why?
|
Oligomenorrhea | 1 | 2006 | 42 | 0.260 |
Why?
|
Amenorrhea | 2 | 2008 | 483 | 0.260 |
Why?
|
Gonadal Hormones | 2 | 2015 | 30 | 0.250 |
Why?
|
Metabolism | 1 | 2006 | 193 | 0.240 |
Why?
|
Gynecology | 1 | 2020 | 528 | 0.240 |
Why?
|
Psychiatric Status Rating Scales | 9 | 2020 | 6011 | 0.230 |
Why?
|
Circadian Rhythm | 5 | 2023 | 2569 | 0.230 |
Why?
|
Treatment Outcome | 25 | 2023 | 64681 | 0.230 |
Why?
|
Serotonin | 1 | 2009 | 1042 | 0.230 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4872 | 0.220 |
Why?
|
United States | 25 | 2024 | 72339 | 0.220 |
Why?
|
Climacteric | 2 | 2002 | 57 | 0.220 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1874 | 0.220 |
Why?
|
Vagina | 3 | 2018 | 841 | 0.220 |
Why?
|
Ovariectomy | 5 | 2020 | 614 | 0.210 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2003 | 140 | 0.210 |
Why?
|
Mental Health | 3 | 2024 | 3251 | 0.200 |
Why?
|
Meditation | 3 | 2021 | 251 | 0.200 |
Why?
|
Antidepressive Agents, Second-Generation | 3 | 2018 | 489 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.200 |
Why?
|
Biomedical Research | 3 | 2020 | 3434 | 0.200 |
Why?
|
Exercise | 8 | 2018 | 5874 | 0.200 |
Why?
|
Young Adult | 11 | 2024 | 59221 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.200 |
Why?
|
Cognition | 6 | 2023 | 6988 | 0.200 |
Why?
|
Severity of Illness Index | 11 | 2019 | 15841 | 0.200 |
Why?
|
Calorimetry, Indirect | 1 | 2022 | 173 | 0.200 |
Why?
|
Acetates | 1 | 2003 | 319 | 0.200 |
Why?
|
Pyridines | 2 | 2011 | 2872 | 0.190 |
Why?
|
Amines | 1 | 2003 | 280 | 0.190 |
Why?
|
Postpartum Period | 1 | 2009 | 1178 | 0.190 |
Why?
|
Piperazines | 2 | 2009 | 2522 | 0.190 |
Why?
|
Follicular Phase | 1 | 2021 | 143 | 0.190 |
Why?
|
Psychotropic Drugs | 1 | 2007 | 885 | 0.190 |
Why?
|
Prospective Studies | 16 | 2024 | 54435 | 0.190 |
Why?
|
Paroxetine | 2 | 2015 | 181 | 0.180 |
Why?
|
Hormone Replacement Therapy | 2 | 2022 | 751 | 0.180 |
Why?
|
Anti-Anxiety Agents | 1 | 2003 | 397 | 0.180 |
Why?
|
Infertility, Female | 1 | 2007 | 761 | 0.180 |
Why?
|
Carbohydrates | 1 | 2022 | 389 | 0.170 |
Why?
|
Body Temperature Regulation | 2 | 2012 | 292 | 0.170 |
Why?
|
Child Abuse | 2 | 2023 | 1076 | 0.170 |
Why?
|
Hyperprolactinemia | 2 | 2013 | 124 | 0.170 |
Why?
|
Epilepsy | 2 | 2008 | 3304 | 0.170 |
Why?
|
Azepines | 1 | 2022 | 328 | 0.170 |
Why?
|
Risk Factors | 19 | 2021 | 74239 | 0.170 |
Why?
|
Men's Health | 1 | 2020 | 73 | 0.170 |
Why?
|
Sleep Arousal Disorders | 1 | 2019 | 12 | 0.170 |
Why?
|
Drug Therapy, Combination | 4 | 2017 | 6304 | 0.170 |
Why?
|
Ovulation | 1 | 2020 | 181 | 0.160 |
Why?
|
Glucocorticoids | 1 | 2009 | 2159 | 0.160 |
Why?
|
Stress, Psychological | 6 | 2024 | 4487 | 0.160 |
Why?
|
Career Mobility | 1 | 2021 | 259 | 0.160 |
Why?
|
Cross-Sectional Studies | 10 | 2022 | 26071 | 0.160 |
Why?
|
Menopause, Premature | 1 | 2020 | 124 | 0.160 |
Why?
|
Sex Factors | 4 | 2021 | 10553 | 0.160 |
Why?
|
Complementary Therapies | 1 | 2022 | 487 | 0.150 |
Why?
|
Tumor Escape | 1 | 2021 | 371 | 0.150 |
Why?
|
Odds Ratio | 6 | 2022 | 9652 | 0.150 |
Why?
|
Melatonin | 1 | 2023 | 668 | 0.150 |
Why?
|
Efficiency | 1 | 2021 | 476 | 0.150 |
Why?
|
Reaction Time | 1 | 2024 | 2087 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3512 | 0.150 |
Why?
|
Cohort Studies | 12 | 2021 | 41496 | 0.150 |
Why?
|
Administration, Cutaneous | 3 | 2011 | 713 | 0.150 |
Why?
|
Recurrence | 4 | 2016 | 8457 | 0.150 |
Why?
|
Logistic Models | 4 | 2018 | 13249 | 0.140 |
Why?
|
Cardiovascular Diseases | 6 | 2022 | 15520 | 0.140 |
Why?
|
Women's Rights | 1 | 2017 | 65 | 0.140 |
Why?
|
Self Report | 7 | 2022 | 3727 | 0.140 |
Why?
|
Anticonvulsants | 2 | 2008 | 1910 | 0.140 |
Why?
|
Mental Health Services | 1 | 2009 | 1716 | 0.140 |
Why?
|
Affective Symptoms | 2 | 2011 | 417 | 0.140 |
Why?
|
Follow-Up Studies | 13 | 2021 | 39126 | 0.140 |
Why?
|
Psychotic Disorders | 2 | 2009 | 3220 | 0.130 |
Why?
|
Triazoles | 1 | 2022 | 902 | 0.130 |
Why?
|
Adolescent | 12 | 2021 | 88298 | 0.130 |
Why?
|
Oxidation-Reduction | 1 | 2022 | 2227 | 0.130 |
Why?
|
Sex Characteristics | 3 | 2021 | 2640 | 0.130 |
Why?
|
Cerebral Cortex | 1 | 2012 | 5775 | 0.130 |
Why?
|
Mentors | 1 | 2021 | 663 | 0.130 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.120 |
Why?
|
Migraine Disorders | 1 | 2008 | 1701 | 0.120 |
Why?
|
Pennsylvania | 1 | 2016 | 612 | 0.120 |
Why?
|
Age Factors | 8 | 2020 | 18384 | 0.120 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2015 | 146 | 0.120 |
Why?
|
Gender Identity | 1 | 2020 | 766 | 0.120 |
Why?
|
Galvanic Skin Response | 2 | 2013 | 358 | 0.120 |
Why?
|
HIV Infections | 2 | 2018 | 17347 | 0.110 |
Why?
|
Body Mass Index | 6 | 2020 | 12952 | 0.110 |
Why?
|
Androgens | 1 | 2021 | 1283 | 0.110 |
Why?
|
Antipsychotic Agents | 3 | 2013 | 3064 | 0.110 |
Why?
|
Exercise Therapy | 2 | 2018 | 922 | 0.110 |
Why?
|
Granulosa Cells | 1 | 2013 | 115 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2014 | 2189 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2016 | 809 | 0.110 |
Why?
|
Telephone | 1 | 2016 | 624 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10218 | 0.100 |
Why?
|
Faculty, Medical | 1 | 2021 | 1205 | 0.100 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2016 | 294 | 0.100 |
Why?
|
Blood Pressure Determination | 1 | 2016 | 633 | 0.100 |
Why?
|
Prevalence | 4 | 2022 | 15721 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2023 | 5250 | 0.100 |
Why?
|
Menorrhagia | 1 | 2012 | 59 | 0.100 |
Why?
|
Blood Pressure | 2 | 2019 | 8479 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1520 | 0.100 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2012 | 107 | 0.100 |
Why?
|
Hospitalization | 2 | 2009 | 10707 | 0.100 |
Why?
|
Leadership | 1 | 2021 | 1385 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2928 | 0.100 |
Why?
|
Mental Disorders | 2 | 2009 | 6823 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2244 | 0.100 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3453 | 0.100 |
Why?
|
Research Design | 2 | 2020 | 6180 | 0.090 |
Why?
|
Internet | 1 | 2023 | 3096 | 0.090 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2014 | 396 | 0.090 |
Why?
|
Single-Blind Method | 3 | 2015 | 1577 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2021 | 22174 | 0.090 |
Why?
|
Placebo Effect | 1 | 2015 | 518 | 0.090 |
Why?
|
Bone Remodeling | 1 | 2014 | 583 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3821 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2022 | 3313 | 0.090 |
Why?
|
Aged | 11 | 2022 | 169288 | 0.090 |
Why?
|
Delayed-Action Preparations | 1 | 2013 | 961 | 0.080 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2018 | 1895 | 0.080 |
Why?
|
Depression, Postpartum | 2 | 2006 | 349 | 0.080 |
Why?
|
Menarche | 2 | 2017 | 532 | 0.080 |
Why?
|
Lithium Compounds | 1 | 2011 | 223 | 0.080 |
Why?
|
Socioeconomic Factors | 3 | 2020 | 7804 | 0.080 |
Why?
|
Monitoring, Ambulatory | 1 | 2012 | 355 | 0.080 |
Why?
|
Menstruation | 2 | 2024 | 307 | 0.080 |
Why?
|
Medication Adherence | 1 | 2020 | 2175 | 0.080 |
Why?
|
Hyperhidrosis | 1 | 2008 | 34 | 0.080 |
Why?
|
Monitoring, Physiologic | 2 | 2015 | 1780 | 0.080 |
Why?
|
Obesity | 3 | 2020 | 12939 | 0.070 |
Why?
|
Heart Rate | 2 | 2019 | 4197 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 1702 | 0.070 |
Why?
|
Primary Ovarian Insufficiency | 2 | 2018 | 107 | 0.070 |
Why?
|
Time Factors | 8 | 2020 | 39957 | 0.070 |
Why?
|
Psychometrics | 1 | 2017 | 3061 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2684 | 0.070 |
Why?
|
Consensus | 3 | 2024 | 3134 | 0.070 |
Why?
|
Glycogen | 2 | 2018 | 251 | 0.070 |
Why?
|
Lipoproteins | 1 | 2012 | 877 | 0.070 |
Why?
|
Dietary Supplements | 3 | 2015 | 3410 | 0.070 |
Why?
|
Testosterone | 3 | 2021 | 2472 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10756 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6345 | 0.070 |
Why?
|
Hirsutism | 1 | 2006 | 68 | 0.070 |
Why?
|
Aging | 3 | 2020 | 8702 | 0.070 |
Why?
|
Lactobacillus | 2 | 2018 | 212 | 0.070 |
Why?
|
Self Concept | 1 | 2012 | 1046 | 0.070 |
Why?
|
Dyspareunia | 2 | 2018 | 48 | 0.070 |
Why?
|
Electroencephalography | 1 | 2021 | 6242 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5666 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2854 | 0.060 |
Why?
|
Gonadal Steroid Hormones | 1 | 2009 | 702 | 0.060 |
Why?
|
Behavior Therapy | 1 | 2010 | 875 | 0.060 |
Why?
|
Incidence | 4 | 2022 | 21365 | 0.060 |
Why?
|
Comorbidity | 5 | 2018 | 10516 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6486 | 0.060 |
Why?
|
Triglycerides | 1 | 2012 | 2457 | 0.060 |
Why?
|
Endometrium | 1 | 2007 | 403 | 0.060 |
Why?
|
Pregnancy | 7 | 2023 | 29893 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4015 | 0.060 |
Why?
|
Risk Assessment | 2 | 2021 | 24021 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2009 | 2082 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2024 | 0.050 |
Why?
|
Hyperplasia | 1 | 2007 | 1150 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 3089 | 0.050 |
Why?
|
Terminology as Topic | 1 | 2010 | 1528 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2010 | 3976 | 0.050 |
Why?
|
Environment | 1 | 2009 | 1122 | 0.050 |
Why?
|
Male | 9 | 2022 | 360693 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2009 | 2928 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5321 | 0.050 |
Why?
|
Social Support | 1 | 2012 | 2175 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2683 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15308 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5333 | 0.050 |
Why?
|
Washington | 1 | 2022 | 314 | 0.050 |
Why?
|
Androstenedione | 1 | 2021 | 131 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13511 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2022 | 276 | 0.040 |
Why?
|
Glucose | 1 | 2012 | 4342 | 0.040 |
Why?
|
Illinois | 1 | 2020 | 120 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8642 | 0.040 |
Why?
|
Parity | 2 | 2017 | 929 | 0.040 |
Why?
|
Biology | 1 | 2022 | 290 | 0.040 |
Why?
|
Health Behavior | 1 | 2011 | 2641 | 0.040 |
Why?
|
Chicago | 1 | 2020 | 254 | 0.040 |
Why?
|
Attitude to Health | 1 | 2008 | 2026 | 0.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 1990 | 0.040 |
Why?
|
Waist-Hip Ratio | 1 | 2020 | 518 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2012 | 3952 | 0.040 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2021 | 550 | 0.040 |
Why?
|
Bone Density | 1 | 2011 | 3546 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2021 | 80674 | 0.040 |
Why?
|
Vulvar Diseases | 1 | 2018 | 64 | 0.040 |
Why?
|
Thinking | 1 | 2021 | 319 | 0.040 |
Why?
|
Preoperative Period | 1 | 2020 | 551 | 0.040 |
Why?
|
Genotype | 1 | 2012 | 12985 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2020 | 15637 | 0.040 |
Why?
|
Bone and Bones | 1 | 2008 | 2568 | 0.040 |
Why?
|
Osteoporosis | 1 | 2007 | 1604 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 998 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13385 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 360 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2017 | 190 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12474 | 0.030 |
Why?
|
Teaching Materials | 1 | 2016 | 84 | 0.030 |
Why?
|
Docosahexaenoic Acids | 2 | 2014 | 906 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6585 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 2006 | 2219 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8998 | 0.030 |
Why?
|
Lactation | 1 | 2017 | 397 | 0.030 |
Why?
|
Overweight | 1 | 2006 | 2418 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1818 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2021 | 3418 | 0.030 |
Why?
|
Orgasm | 1 | 2014 | 62 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2016 | 221 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14025 | 0.030 |
Why?
|
Procollagen | 1 | 2014 | 187 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2006 | 7046 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1246 | 0.030 |
Why?
|
Atrophy | 1 | 2018 | 1633 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22140 | 0.030 |
Why?
|
Reference Values | 1 | 2020 | 4921 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2007 | 2949 | 0.030 |
Why?
|
Inflammation | 2 | 2023 | 10759 | 0.030 |
Why?
|
Follicle Stimulating Hormone, Human | 1 | 2012 | 25 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12052 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3210 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2021 | 6223 | 0.030 |
Why?
|
Linear Models | 2 | 2012 | 5869 | 0.020 |
Why?
|
Child | 5 | 2023 | 80152 | 0.020 |
Why?
|
Pain | 1 | 2007 | 5072 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36415 | 0.020 |
Why?
|
Patient Selection | 2 | 2014 | 4246 | 0.020 |
Why?
|
Selection Bias | 1 | 2013 | 359 | 0.020 |
Why?
|
Humidity | 1 | 2012 | 205 | 0.020 |
Why?
|
Collagen Type I | 1 | 2014 | 616 | 0.020 |
Why?
|
Quality Control | 1 | 2014 | 833 | 0.020 |
Why?
|
Models, Psychological | 1 | 2015 | 830 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 12976 | 0.020 |
Why?
|
Schizophrenia | 1 | 2009 | 6930 | 0.020 |
Why?
|
Eicosapentaenoic Acid | 1 | 2014 | 561 | 0.020 |
Why?
|
Hypogonadism | 1 | 2016 | 798 | 0.020 |
Why?
|
Blood Glucose | 2 | 2016 | 6392 | 0.020 |
Why?
|
Electrodes | 1 | 2012 | 611 | 0.020 |
Why?
|
Social Environment | 1 | 2015 | 1022 | 0.020 |
Why?
|
Animals | 1 | 2021 | 168079 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2706 | 0.020 |
Why?
|
Laboratories | 1 | 2012 | 462 | 0.020 |
Why?
|
Glucuronides | 1 | 2007 | 20 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3873 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2691 | 0.020 |
Why?
|
Psychological Tests | 1 | 2010 | 639 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29687 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2510 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2014 | 2359 | 0.020 |
Why?
|
Massachusetts | 2 | 2013 | 8837 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12728 | 0.020 |
Why?
|
Norethindrone | 1 | 2006 | 56 | 0.020 |
Why?
|
Primary Health Care | 1 | 2002 | 4678 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9616 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4642 | 0.020 |
Why?
|
Hospitals, Psychiatric | 1 | 2007 | 318 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 1965 | 155 | 0.020 |
Why?
|
Rh-Hr Blood-Group System | 1 | 1965 | 64 | 0.020 |
Why?
|
Erythroblastosis, Fetal | 1 | 1965 | 62 | 0.020 |
Why?
|
Acid-Base Equilibrium | 1 | 1965 | 181 | 0.010 |
Why?
|
Marital Status | 1 | 2006 | 425 | 0.010 |
Why?
|
Sweden | 1 | 2007 | 1379 | 0.010 |
Why?
|
Blood Chemical Analysis | 1 | 1965 | 436 | 0.010 |
Why?
|
Societies, Medical | 1 | 2015 | 3923 | 0.010 |
Why?
|
Pain Measurement | 1 | 2012 | 3549 | 0.010 |
Why?
|
Peptides | 1 | 2014 | 4353 | 0.010 |
Why?
|
Brain | 1 | 2009 | 27092 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2014 | 5103 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2016 | 3417 | 0.010 |
Why?
|
Homeostasis | 1 | 2012 | 3320 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2006 | 1336 | 0.010 |
Why?
|
Decision Making | 1 | 2015 | 3931 | 0.010 |
Why?
|
Memory | 1 | 2010 | 2190 | 0.010 |
Why?
|
Body Composition | 1 | 2009 | 2427 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20119 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1965 | 1303 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9457 | 0.010 |
Why?
|
Software | 1 | 2012 | 4431 | 0.010 |
Why?
|
Fetus | 1 | 1965 | 1864 | 0.010 |
Why?
|
Insulin | 1 | 2012 | 6588 | 0.010 |
Why?
|
Plasmapheresis | 1 | 1978 | 207 | 0.010 |
Why?
|
Antibodies | 1 | 1965 | 2415 | 0.010 |
Why?
|
Life Style | 1 | 2008 | 3907 | 0.010 |
Why?
|
Motor Activity | 1 | 2006 | 2712 | 0.010 |
Why?
|
Mothers | 1 | 2006 | 2193 | 0.010 |
Why?
|
Patient Readmission | 1 | 2007 | 3265 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 12159 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 1978 | 1141 | 0.010 |
Why?
|
Registries | 1 | 2007 | 8247 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2005 | 4575 | 0.000 |
Why?
|
Heart Conduction System | 1 | 1946 | 1008 | 0.000 |
Why?
|
Tachycardia, Ventricular | 1 | 1946 | 1305 | 0.000 |
Why?
|
Arrhythmias, Cardiac | 1 | 1946 | 2247 | 0.000 |
Why?
|
Lipoproteins, LDL | 1 | 1978 | 643 | 0.000 |
Why?
|
Lipoproteins, HDL | 1 | 1978 | 675 | 0.000 |
Why?
|
Homozygote | 1 | 1978 | 1775 | 0.000 |
Why?
|
Heart | 1 | 1946 | 4431 | 0.000 |
Why?
|
Electrocardiography | 1 | 1946 | 6387 | 0.000 |
Why?
|
Cholesterol | 1 | 1978 | 2902 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1965 | 26199 | 0.000 |
Why?
|
Brugada Syndrome | 1 | 1946 | 93 | 0.000 |
Why?
|
Child, Preschool | 1 | 1978 | 42224 | 0.000 |
Why?
|